Bio

Erica Hall is a managing director in Evercore’s strategic advisory practice focused on the biopharma sector. Since joining Evercore in 2016, Ms. Hall’s select transactions include advising Bristol-Myers Squibb on its acquisitions of Celgene and Mirati Therapeutics, and Takeda on its acquisitions of Shire and Nimbus Therapeutics’ TYK2 inhibitor. Ms. Hall has also completed a variety of financing transactions for Madrigal Pharmaceuticals, Royalty Pharma and Halozyme Therapeutics, among other clients. Prior to Evercore, Ms. Hall worked in equity capital markets at Cowen and Co., and in capital markets and investor development at Developing World Markets, an impact investment fund manager. Ms. Hall earned a B.S. in business administration from Bucknell University, an MBA from University of Pennsylvania’s Wharton School and an M.A. in international studies from the University of Pennsylvania.